Trial Profile
A phase I study of the combination of daily oral pazopanib with intravenous docetaxel in patients with advanced solid malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms Pado
- 01 Feb 2015 Status changed from recruiting to completed, according to results published in the Cancer Chemotherapy and Pharmacology.
- 10 May 2010 New trial record